SILKSilk Road Medical Inc

Nasdaq silkroadmed.com


$ 19.22 $ -1.33 (-6.47 %)    

Wednesday, 08-May-2024 15:59:55 EDT
QQQ $ 439.55 $ -0.26 (-0.06 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.18 $ -0.55 (-0.61 %)
GLD $ 213.58 $ -0.63 (-0.29 %)
$ 19.23
$ 20.22
$ 0.00 x 0
$ 0.00 x 0
$ 19.22 - $ 20.50
$ 6.08 - $ 42.99
467,414
na
755M
$ 1.49
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 02-28-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-01-2022 12-31-2021 10-K
11 11-09-2021 09-30-2021 10-Q
12 08-06-2021 06-30-2021 10-Q
13 05-10-2021 03-31-2021 10-Q
14 03-01-2021 12-31-2020 10-K
15 11-16-2020 09-30-2020 10-Q
16 08-13-2020 06-30-2020 10-Q
17 05-15-2020 03-31-2020 10-Q
18 03-02-2020 12-31-2019 10-K
19 11-13-2019 09-30-2019 10-Q
20 08-13-2019 06-30-2019 10-Q
21 05-15-2019 03-31-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jp-morgan-maintains-neutral-on-silk-road-medical-raises-price-target-to-21

JP Morgan analyst Robbie Marcus maintains Silk Road Medical (NASDAQ:SILK) with a Neutral and raises the price target from $1...

 piper-sandler-maintains-neutral-on-silk-road-medical-raises-price-target-to-20

Piper Sandler analyst Adam Maeder maintains Silk Road Medical (NASDAQ:SILK) with a Neutral and raises the price target from ...

 silk-road-medical-q1-2024-gaap-eps-036-beats-040-estimate-sales-48484m-beat-44676m-estimate

Silk Road Medical (NASDAQ:SILK) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0...

 reported-earlier-genesis-medtech-collaborates-with-silk-road-medical-to-combat-stroke-risk-in-china-with-advanced-tcar-technology

TCAR (Transcarotid Artery Revascularization) is an innovative minimally invasive surgical procedure used to treat carotid arter...

 argus-research-upgrades-silk-road-medical-to-buy-announces-24-price-target

Argus Research analyst Steve Silver upgrades Silk Road Medical (NASDAQ:SILK) from Hold to Buy and announces $24 price target.

 stifel-maintains-buy-on-silk-road-medical-raises-price-target-to-23

Stifel analyst Rick Wise maintains Silk Road Medical (NASDAQ:SILK) with a Buy and raises the price target from $20 to $23.

 jp-morgan-maintains-neutral-on-silk-road-medical-raises-price-target-to-19

JP Morgan analyst Robbie Marcus maintains Silk Road Medical (NASDAQ:SILK) with a Neutral and raises the price target from $1...

 top-3-health-care-stocks-you-may-want-to-dump-in-q1

As of Feb. 29, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as...

 piper-sandler-maintains-neutral-on-silk-road-medical-raises-price-target-to-18

Piper Sandler analyst Adam Maeder maintains Silk Road Medical (NASDAQ:SILK) with a Neutral and raises the price target from ...

 silk-road-medical-q4-2023-gaap-eps-033-beats-042-estimate-sales-4727m-beat-4197m-estimate

Silk Road Medical (NASDAQ:SILK) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0...

 earnings-scheduled-for-february-28-2024

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenu...

 heart-devices-focused-silk-road-medical-stock-gets-an-upgrade---analyst-says-new-ceos-initiatives-sets-stage-for-back-on-track

Stifel's upgraded outlook on Silk Road Medical as CEO Chas McKhann addresses concerns, unveils a compelling vision, and out...

 why-transcode-therapeutics-shares-are-trading-lower-by-over-24-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION